Expertin

Assoc.Prof.Priv.Doz.Dr.med. and Dr. phil Jolanta Siller-Matula

Awards and Grants:

Young Leadership Recognition Program in Interventional Cardiology, CRT 2019
TEAM in AF, European Leadership Promotion Program in Atrial Fibrillation, 2015
Award for the best Habilitation by the Association for the Promotion of Science and Research (Verein zur Förderung von Wissenschaft und Forschung), 2014
Award by the Department of Culture of the City of Vienna for an excellent scientific track record in medical research, 2014
Karl Link Early Career Investigator Award in Thrombosis by the American Heart Association, 2013
Research Grant founded by Roche, 2012
Werner Klein Award for “the best translational research paper” by the Austrian Society of Cardiology; “ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion”, 2012
Best Poster Award, “Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study”, Eurothrombosis 2012
Research Grant by the Austrian Society of Cardiology, 2012
Second prize in the category “best clinical paper” by the Austrian Society of Cardiology; “Phenotyping versus Genotyping for Prediction of Clopidogrel Efficacy and Safety: the PEGASUS-PCI study”, 2012
Dr. Maria Schaumayer Award for the PhD Thesis, 2011
Science Slam Champion, Vienna 2010
Travel Award by the Vienna Science and Technology Fund, Euro Science Open Forum, Turin, Italy 2010
Researcher of the Month, Medical University of Vienna, 2009
First prize in the category “best clinical paper” by the Austrian Society of Cardiology; “Calcium-channel blockers reduce the antiplatelet effect of clopidogrel”, 2009
Best Poster Award; “Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel”, Conference of the Society of Thrombosis and Haemostasis, 2009
Travel Award by the British Council, Euro Science Open Forum, Barcelona 2008
 Travel Award by the Austrian Research Association, Scientific Sessions of the American Heart Association, New Orleans, 2008
 Ebrantil Congress Award, Munich 2008
 Austrian Radio Award and Second Prize of Jury in the FameLab, 2008
 Research Grant, Austrian Nationalbank (Nr. 12565), 2007
 Achievement Award, Medical University of Vienna, 2004
 Research Grant, Medical University of Vienna, 2004
 Achievement Award, Polish Ministry of Health, 2003
 Erasmus Scholarship, Medical University of Vienna, 2003
 Achievement Award, Polish Ministry of Health, 2003
 Best Abstract Award, “The air microflora of swimming pools using different methods of water disinfection”, Scientific Conference, Gdansk, Poland, 2002
 Achievement Award, Medical University of Warsaw, 2001

Prize in the Academic Competition in Anatomy Scapula Aurea, Medical University of Warsaw, 2001

Peer reviewed publications listed in Pub-med:

1.             Hengstenberg C and Siller-Matula JM. Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI. J Am Coll Cardiol. 2019;73:2829-2831.

2.             Winter MP, von Lewinski D, Wallner M, Pruller F, Kolesnik E, Hengstenberg C and Siller-Matula JM. Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study. Scientific reports. 2019;9:8194.

3.             Eyileten C, Soplinska AM, Pordzik J, Siller-Matula JM and Postula M. Effectiveness of antiplatelet drugs under therapeutic hypothermia a comprehensive review. Clin Pharmacol Ther. 2019.

4.             Siller-Matula JM, Hofer F, Goliasch G, Andreas M, Mascherbauer J and Hengstenberg C. [Aortic valve disease]. MMW Fortschr Med. 2019;161:42-46.

5.             Komosa A, Lesiak M, Krasinski Z, Grygier M, Siniawski A, Skorupski W, Olasinska-Wisniewska A, Pyda M, Araszkiewicz A, Mitkowski P, Grajek S, Mularek-Kubzdela T, Hengstenberg C and Siller-Matula JM. Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis. Thromb Haemost. 2019.

6.             Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Ricci F, Kirchhof P and De Caterina R. Net Clinical Benefit of Non-Vitamin K Antagonist Versus Vitamin K Antagonist Anticoagulants in Elderly Patients With Atrial Fibrillation. Am J Med. 2019.

7.             Renda G, Patti G, Lang IM, Siller-Matula JM, Hylek EM, Ambrosio G, Haas S, De Caterina R and Working Group on Thrombosis of the Italian Society of C. Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. Int J Cardiol. 2019;286:198-207.

8.             Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R and Kirchhof P. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019;9:e022478.

9.             Winter MP, Schneeweiss T, Cremer R, Biesinger B, Hengstenberg C, Pruller F, Wallner M, Kolesnik E, von Lewinski D, Lang IM and Siller-Matula JM. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest. 2019:e13102.

10.          Gasecka A, Konwerski M, Pordzik J, Soplinska A, Filipiak KJ, Siller-Matula JM and Postula M. Switching between P2Y12 antagonists - From bench to bedside. Vascular pharmacology. 2019.

11.          Sikora J, Niezgoda P, Baranska M, Buszko K, Skibinska N, Sroka W, Pstragowski K, Siller-Matula J, Bernd J, Gorog D, Navarese EP, Marszall MP and Kubica J. METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial. Thromb Haemost. 2018.

12.          Pruller F, Bis L, Milke OL, Fruhwald F, Patzold S, Altmanninger-Sock S, Siller-Matula J, von Lewinski F, Ablasser K, Sacherer M and von Lewinski D. Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients. J Clin Med. 2018;7.

13.          Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P and De Caterina R. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol. 2018;270:160-166.

14.          Hengstenberg C and Siller-Matula JM. Coming Closer to Personalized Medicine in Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018;11:1730-1732.

15.          Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R and group TiA. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. Int J Cardiol. 2018:doi: 10.1016/j.ijcard.2018.04.093.

16.          Pruller F, Milke OL, Bis L, Fruhwald F, Scherr D, Eller P, Patzold S, Altmanninger-Sock S, Rainer P, Siller-Matula J and von Lewinski D. Impaired aspirin-mediated platelet function inhibition in resuscitated patients with acute myocardial infarction treated with therapeutic hypothermia: a prospective, observational, non-randomized single-centre study. Annals of intensive care. 2018;8:28.

17.          Milanowski L, Rasul F, Gajda SN, Eyileten C, Siller-Matula J and Postula M. Genetic Variability of SRC Family Kinases and Its Association with Platelet Hyperreactivity and Clinical Outcomes: A Systematic Review. Curr Pharm Des. 2018;24:628-640.

18.          Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM and Postula M. Ticagrelor - toward more efficient platelet inhibition and beyond. Therapeutics and clinical risk management. 2018;14:129-140.

19.          Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozdz J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, Siller-Matula JM, Witkowski A, Kuliczkowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M and Wojcik J. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts' standpoint. Cardiol J. 2018:doi: 10.5603/CJ.a2018.0042.

20.          Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Dery JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR and Investigators I. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J. 2018;198:152-159.

21.          Schoergenhofer C, Hobl EL, Schellongowski P, Heinz G, Speidl WS, Siller-Matula JM, Schmid M, Sunder-Plassmann R, Stimpfl T, Hackl M and Jilma B. Clopidogrel in Critically Ill Patients. Clin Pharmacol Ther. 2018;103:217-223.

22.          Schoergenhofer C, Hobl EL, Staudinger T, Speidl WS, Heinz G, Siller-Matula J, Zauner C, Reiter B, Kubica J and Jilma B. Prasugrel in critically ill patients. Thromb Haemost. 2017;117:1582-1587.

23.          Komosa A, Rzymski P, Perek B, Ropacka-Lesiak M, Lesiak M, Siller-Matula JM and Poniedzialek B. Platelets redox balance assessment: Current evidence and methodological considerations. Vascular pharmacology. 2017:in press.

24.          Winter MP, Grove EL, De Caterina R, Gorog DA, Ahrens I, Geisler T, Gurbel PA, Tantry U, Navarese EP and Siller-Matula JM. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. European heart journal Cardiovascular pharmacotherapy. 2017;3:221-234.

25.          Kubica J, Adamski P, Paciorek P, Ladny JR, Kalarus Z, Banasiak W, Kochman W, Goracy J, Wozakowska-Kaplon B, Navarese EP, Kleinrok A, Gil R, Lesiak M, Drozdz J, Kubica A, Filipiak KJ, Kazmierczak J, Goch A, Grajek S, Basinski A, Szarpak L, Grzesk G, Hoffman P, Wojakowski W, Gasior Z, Dobrzycki S, Siller-Matula JM, Witkowski A, Kuliczkowski W, Gruchala M, Timler D, Opolski G, Dudek D, Legutko J, Zielinska M and Wojcik J. Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts' standpoint. Kardiol Pol. 2017;75:399-408.

26.          Niezgoda P, Sikora J, Baranska M, Sikora A, Buszko K, Sieminska E, Marszall MP, Siller-Matula JM, Jilma B, Alexopoulos D, Fabiszak T and Kubica J. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017;117:718-726.

27.          Navarese EP, Kolodziejczak M, Winter MP, Alimohammadi A, Lang IM, Buffon A, Lip GY and Siller-Matula JM. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol. 2017;227:644-649.

28.          Siller-Matula JM, Specht S, Kubica J, Alexopoulos D, De Caterina R, Hobl EL, Jilma B, Christ G and Lang IM. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol. 2016;82:1343-1350.

29.          Siller-Matula JM, Akca B, Neunteufl T, Maurer G, Lang IM, Kreiner G, Berger R and Delle-Karth G. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets. 2016;27:373-7.

30.          Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, Siller-Matula JM, Dabrowska A, Fabiszak T, Kozinski M and Gurbel PA. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016;215:201-208.

31.          Siller-Matula JM, Hintermeier A, Kastner J, Kreiner G, Maurer G, Kratochwil C, Lang IM and Delle-Karth G. Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascular pharmacology. 2016;79:6-10.

32.          Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D and Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37:245-52.

33.          Komosa A, Siller-Matula JM, Lesiak M, Michalak M, Kowal J, Maczynski M, Siniawski A, Mularek-Kubzdela T, Wisniewski S and Grajek S. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. Thromb Res. 2016;138:49-54.

34.          Winter MP, Kozinski M, Kubica J, Aradi D and Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology. 2015;11:259-80.

35.          Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K and European Platelet A. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer? Thromb Haemost. 2015;113:37-52.

36.          Siller-Matula JM, Petre A, Delle-Karth G, Huber K, Ay C, Lordkipanidze M, De Caterina R, Kolh P, Mahla E and Gersh BJ. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. European heart journal Acute cardiovascular care. 2015;DOI: 10.1177/2048872615585516.

37.          Siller-Matula JM, Gruber C, Francesconi M, Dechant C, Jilma B, Delle-Karth G, Grohs K, Podczeck-Schweighofer A and Christ G. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Sci (Lond). 2015;128:121-30.

38.          Ozsoy M, Klatte T, Wiener H, Siller-Matula J and Schmidbauer J. Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section. Urologic oncology. 2015;33:67 e25-9.

39.          Droppa M, Tschernow D, Muller KA, Tavlaki E, Karathanos A, Stimpfle F, Schaeffeler E, Schwab M, Tolios A, Siller-Matula JM, Gawaz M and Geisler T. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One. 2015;10:e0121620.

40.          Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW and Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;in press.

41.          Siller-Matula JM, Trenk D, Krahenbuhl S, Michelson AD and Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014;12:2-13.

42.          Siller-Matula JM, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J and Jilma B. Interplay between Genetic and Clinical Variables Affecting Platelet Reactivity and Cardiac Adverse Events in Patients Undergoing Percutaneous Coronary Intervention. PLoS One. 2014;9:e102701.

43.          Siller-Matula JM and Delle Karth G. [Dual platelet inhibitors in intensive care units.]. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2014:1-8.

44.          Siller-Matula JM, Arbesu I, Jilma B, Maurer G, Lang IM and Mannhalter C. Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention. Thromb Haemost. 2014;111:1060-6.

45.          Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, Jeong YH, Fabiszak T, Andruszkiewicz A and Gurbel PA. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Curr Med Res Opin. 2014;doi: 10.1185/03007995.2014.880050.

46.          Kubica A, Kasprzak M, Siller-Matula J, Kozinski M, Pio Navarese E, Obonska K, Andruszkiewicz A, Sztuba B, Fabiszak T, Swiatkiewicz I, Paciorek P and Kubica J. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol. 2014;742:47-54.

47.          Kozinski M, Obonska K, Stankowska K, Navarese EP, Fabiszak T, Stolarek W, Kasprzak M, Siller-Matula JM, Rosc D, Kubica J and De Servi S. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol J. 2014;doi: 10.5603/CJ.a2014.0026.:in press.

48.          Komosa A, Siller-Matula JM, Kowal J, Lesiak M, Siniawski A, Maczynski M, Michalak M, Mularek-Kubzdela T and Grajek S. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb. Platelets. 2014;in press.

49.          Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, Pirker-Kees A and Siller-Matula JM. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke. 2014;45:492-503.

50.          Christ G, Siller-Matula JM, Francesconi M, Dechant C, Grohs K and Podczeck-Schweighofer A. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open. 2014;4:e005781.

51.          Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA and Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-73.

52.          Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K and Epa. Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality. JACC Cardiovasc Interv. 2013;6:1111-28.

53.          Siller-Matula JM and Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost. 2013;110:628-31.

54.          Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A and Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol. 2013;167:2018-23.

55.          Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, Tolios A, Drucker C and Jilma B. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol. 2013;167:430-5.

56.          Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E and Podczeck-Schweighofer A. Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy. Thromb Res. 2013;132:e36-e41.

57.          Steinhauser G, Adlassnig W, Risch JA, Anderlini S, Arguriou P, Armendariz AZ, Bains W, Baker C, Barnes M, Barnett J, Baumgartner M, Siller-Matula J, et al. Peer review versus editorial review and their role in innovative science. Theor Med Bioeth. 2012;33:359-76.

58.          Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM and Jilma B. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial. Clin Sci (Lond). 2012;123:591-600.

59.          Siller-Matula JM, Miller I, Gemeiner M, Plasenzotti R, Bayer G, Mesteri I, Fabry A, Petroczi K, Nobauer K, Razzazi-Fazeli E, Planchon S, Renaut J, Quehenberger P, Selzer E and Jilma B. Continuous thrombin infusion leads to a bleeding phenotype in sheep. Thromb Res. 2012;130:226-36.

60.          Siller-Matula JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, Pendergrast PS, Chung JK, Tian X, Schaub RG and Jilma B. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol. 2012;32:902-9.

61.          Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K and Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost. 2012;10:529-42.

62.          Siller-Matula JM. Hemorrhagic complications associated with aspirin: an underestimated hazard in clinical practice? Jama. 2012;307:2318-20.

63.          Schror K, Siller-Matula JM and Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol. 2012;26:39-46.

64.          Heinisch BB, Vcelar B, Kapiotis S, Blann A, Wolzt M, Siller-Matula JM and Jilma B. The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers. Platelets. 2012;23:352-8.

65.          Grzesk G, Kozinski M, Navarese EP, Krzyzanowski M, Grzesk E, Kubica A, Siller-Matula JM, Castriota F and Kubica J. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thromb Res. 2012;130:65-9.

66.          Yukhanyan L, Freynhofer MK, Siller-Matula J, Schror K and Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost. 2011;105:Suppl 1:S55-9.

67.          Tentzeris I, Siller-Matula J, Farhan S, Jarai R, Wojta J and Huber K. Platelet function variability and non-genetic causes. Thromb Haemost. 2011;105:Suppl 1:S60-6.

68.          Spiel AO, Bartko J, Schwameis M, Firbas C, Siller-Matula J, Schuetz M, Weigl M and Jilma B. Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration. A randomised controlled trial. Thromb Haemost. 2011;105:655-62.

69.          Siller-Matula JM, Schwameis M, Blann A, Mannhalter C and Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost. 2011;106:1020-33.

70.          Siller-Matula JM and Jilma B. Response to letter by Lin et al. "Clopidogrel loading dose in patients undergoing elective percutaneous coronary intervention". Heart. 2011;97:2011.

71.          Siller-Matula JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H and Jilma B. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a Systematic Review and Meta-analysis. Heart. 2011;97:98-105.

72.          Siller-Matula JM and Delle-Karth G. Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding. Evid Based Med. 2011;16:144-5.

73.          Siller-Matula JM. Thrombin as a multifunctional enzyme: Establishing experimental models to study thrombin effects. Südwestdeutscher Verlag für Hochschulschriften. 2011;ISBN-10: 3838129083:1-96.

74.          Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, Gibson CM, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, De Servi S and Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011;9:1902-15.

75.          Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, Siller-Matula JM, Rosc D and Kubica J. Diurnal variation in platelet inhibition by clopidogrel. Platelets. 2011;22:579-87.

76.          Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC and Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105:545-52.

77.          Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-Matula J and Huber K. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. Thromb Haemost. 2010;104:1211-8.

78.          Spiel AO, Siller-Matula J, Firbas C, Leitner JM, Russmueller G and Jilma B. Single dose granulocyte colony-stimulating factor markedly enhances shear-dependent platelet function in humans. Platelets. 2010;21:464-9.

79.          Siller-Matula JM, Tentzeris I, Vogel B, Schacherl S, Jarai R, Geppert A, Unger G and Huber K. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points. Clin Res Cardiol. 2010;99:645-50.

80.          Siller-Matula JM, Jilma B, Schror K, Christ G and Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2624-41.

81.          Siller-Matula JM and Jilma B. Ticagrelor: from discovery to Phase III clinical trial. Future Cardiology. 2010;6:753-64.

82.          Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K and Jilma B. Multiple Electrode Aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost. 2010;8:351-9.

83.          Siller-Matula JM, Bayer G, Bergmeister H, Quehenberger P, Petzelbauer P, Friedl P, Mesteri I and Jilma B. An experimental model to study isolated effects of thrombin in vivo. Thromb Res. 2010;126:454-61.

84.          Mayr FB, Knobl P, Jilma B, Siller-Matula JM, Wagner PG, Schaub RG, Gilbert JC and Jilma-Stohlawetz P. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion. 2010;50:1079-87.

85.          Firbas C, Siller-Matula JM and Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010;8:1689-701.

86.          Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G and Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157:148.e1-148.e5.

87.          Siller-Matula JM, Krumphuber J and Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease. British Journal of Pharmacology. 2009;159:502-17.

88.          Siller-Matula JM and Jilma B. Response to letter by Tho: "Do the association of cytochrome P450 interacting drugs, influence clopidogrel efficacity?". Am Heart J. 2009;158:e9.

89.          Siller-Matula JM and Jilma B. Response to Letter by van Werkum: "Proton pump inhibitors and clopidogrel: a difficult dilemma". Am Heart J. 2009;157:e45.

90.          Siller-Matula JM, Haberl K, Prillinger K, Panzer S, Lang I and Jilma B. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res. 2009;123:874-80.

91.          Siller-Matula JM, Gouya G, Wolzt M and Jilma B. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost. 2009;102:397-403.

92.          Kasprzak M, Kozinski M, Bielis L, Boinska J, Plazuk W, Marciniak A, Budzynski J, Siller-Matula J, Rosc D and Kubica J. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J. 2009;16:535-44.

93.          Siller-Matula JM, Plasenzotti R, Spiel A, Quehenberger P and Jilma B. Interspecies differences in coagulation profile. Thromb Haemost. 2008;100:397-404.

94.          Siller-Matula JM, Panzer S and Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets. 2008;19:551-4.

95.          Siller-Matula JM, Lang I, Christ G and Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52:1557-63.

96.          Siller-Matula JM and Jilma B. Strain differences in toxic effects of long-lasting isoflurane anaesthesia between Wistar rats and Sprague Dawley rats. Food Chem Toxicol. 2008;46:3550-2.

97.          Siller-Matula J, Schror K, Wojta J and Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost. 2007;97:385-93.

Invited review articles in German language not listed in pub-med and book chapters:

1.              Siller-Matula JM. Antikoagulation plus Plättchenhemmung: Welche Kombination zeigt Vorteile in der  AUGUSTUS-Studie? Universum Innere Medizin 2019;04:80-81.

2.              Hofer F, Hengstenberg C, Siller-Matula JM. Antithrombotische Therapie nach TAVI. J Kardiol 2018;26:126-31.

3.              Winter MP, Siller-Matula J. Was empfehlen die Guidelines? NSTEMI – welche Antiplättchentherapie für wen? Jatros: Kardiologie & Gefäßmedizin 2016;3:62-64.

4.              Siller-Matula JM. Aktuelles: Vorbehandlung mit P2Y12-Rezeptorinhibitoren bei Patienten mit NSTE-ACS. J Kardiol 2015;22:7-8.

5.              Specht S, Siller-Matula JM. NSTE-ACS bei VHF: Management bei vorbestehender Therapie mit DOAK. Jatros: Kardiologie & Gefäßmedizin 2014;3:24-25.

6.              Siller-Matula J. Akutes Koronarsyndrom: Entscheidungskriterien für die Wahl des Plättchenhemmers. Arzt und Praxis 2014;68:18-20.

7.              Siller-Matula JM. Prasugrel: Management des ACS- Patienten mit Diabetes. Universum Innere Medizin 2013;08:32-33.

8.              Siller-Matula JM. Aktuelles: Management des Diabetes-ACS-Patienten mit Prasugrel. J Hyperton 2013;17:168-9.

9.              Siller-Matula JM. Nutzen-Risiko-Profil von Aspirin in der Primär- und Sekundärprävention. J Hyperton 2013;17:117-8.

10.           Siller-Matula J, Huber K. Klinische Studien mit neuen Plättchenfunktionshemmern in K. Schrör & W. Kirch (eds) Pharmakologie und Klinik neuer Antiplättchensubstanzen. Schattauer 2013:23-46.

11.           Huber K, Siller-Matula J, Schrör K. Antiplättchentherapie -aktueller Stand und zukünftige Entwicklungen in K. Schrör & W. Kirch (eds) Pharmakologie und Klinik neuer Antiplättchensubstanzen. Schattauer 2013:155-164.

12.           Akca B, Siller-Matula JM. Platelet Function Testing: Expectations and Reality. J Kardiol 2013;20:160–7.

13.           Siller-Matula JM. Das Ansprechen auf die Plättchenhemmung messen: Individualisierte Anti-Plättchen-Therapie. Universum Innere Medizin 2012;09:45-46.

14.           Siller-Matula JM. Individualisierte Anti-Plättchen-Therapie. Universum Innere Medizin 2012;8:32-33.

15.           Siller-Matula JM. Der Thrombozyt beim ACS. in Alber H. (eds) Thrombozytenhemmung beim akuten Koronarsyndrom. Unimed Verlag 2012:31-40.

16.           Siller-Matula JM. Thrombozytenaggregationshemmung: Nicht alle Patienten sind gleich. Universum Innere Medizin 2012;7:18.

17.           Siller-Matula JM. Protonenpumpenhemmer 2011: Gut für den Magen, schlecht für das Herz? Universum Innere Medizin 2011;8:10.

18.           Jilma B, Siller-Matula JM. Ticagrelor zur Behandlung des akuten Koronarsydroms. Pharmainformation 2011;26:2.

19.           Siller-Matula JM, Firbas C, Jilma B. Plättchenaggregationshemmer-Kontrolle der Wirkung: wie und bei wem? Universum Innere Medizin 2010;08:66-67.

20.           Siller-Matula JM. Gleichzeitige Behandlung mit Clopidogrel und PPI Auswirkungen auf die klinische Prognose. Jatros 2010;4:48-49.

21.           Jilma B, Siller-Matula JM. Behandlung kardiovaskulärer Erkrankungen mit derzeit verfügbaren oralen Plättchenhemmern (Acetylsalicylsäure, Clopidogrel, Prasugrel). Pharmainformation 2010;25:3-5.

22.           Siller-Matula JM. Plättcheninhibitoren in der Prävention der KHK. Leading Opinions 2009;4:9-11.

23.           Siller-Matula JM. Indikationen für Plättchen-Inhibitoren in der Primär- und Sekundärprävention. Wiener Medizinische Wochenschrift 2009;7:23-24.

24.           Siller-Matula J. Koronare Herzkrankheit: Plättcheninhibitoren in der Prävention der KHK. Jatros 2009;5:12-15.

25.           Höchtl T, Schrör K, Siller-Matula JM, Freynhofer M, Wojta J, Huber K. Prasugrel, ein neues Thienopyridin. Kariololgie Journal 2009;16:5-6.

26.           Christ G, Siller-Matula J, Huber K. Antithrombotische Behandlung nach einer Koronarstent-Implantation. Universum Innere Medizin 2009;07:76-78.

27.           Siller-Matula JM, Jilma B. Aspirin - Resistenz. Universum Innere Medizin 2008;04:20-21.